San Diego-based Dexcom says this makes it the first continuous glucose monitor (CGM) manufacturer to integrate GenAI into this technology. The new platform analyzes individual health data patterns. It could reveal a direct association between lifestyle choices and glucose levels and provide actionable insights to improve metabolic health.
Dexcom said Stelo — its FDA-cleared over-the-counter glucose biosensor — is now its first product to use GenAI-enabled technology to produce weekly insights. It plans to begin rolling out these new “Weekly Insights” features this week. The technology offers users more personalized tips, recommendations and education related to diet, exercise and sleep. The Stelo app then contextualizes these findings for the user.
According to a news release, Dexcom leveraged Google Cloud’s Vertex AI platform and Gemini models to build the GenAI platform. This marks the latest significant digital health play for Dexcom, which last month partnered with smart ring maker Oura.
“The launch of our GenAI platform reinforces our long-standing reputation as the glucose biosensing leader and opens the door for future advancements across our product portfolio,” said Jake Leach, EVP and COO at Dexcom. “Innovation is at the core of what we do. We look forward to introducing additional GenAI-powered features over the next year to help users contextualize their health information and make proactive, informed lifestyle decisions.”
